摘要
目的探讨剂量密集新辅助化疗方案治疗乳腺癌的疗效和安全性。方法 51例乳腺癌患者应用剂量密集表阿霉素联合环磷酰胺(EC)序贯紫杉醇(P)新辅助化疗方案,14 d为1个周期,共4周期。结果全组中1、9、8、9、24例患者完成了3、4、5、6、8周期的新辅助化疗,p CR率17.6%(9/51),RR为82.4%;ER、PR均阴性的RR率高于ER和/或PR阳性的患者(P<0.05或P<0.01);全组患者均未出现4级不良反应,主要3级不良反应为中性粒细胞下降5.9%和神经毒性2.0%;1、2、3年DFS和OS分别为96.0%、91.0%、83.0%和100%、95.0%、91.0%。结论剂量密集EC序贯P新辅助化疗方案疗效较好,安全性较高,是乳腺癌可以优选的新辅助化疗方案。
Objective To explore the efficacy and safety of dose-dense neoadjuvant chemotherapy（ DDNACT） in the treatment of breast cancer. Methods A total of 51 patients with breast cancer received neoadjuvant chemotherapy with dose-dense epirubicin（ E-ADM） and cyclophosphamide（ CTX）（ EC protocol） with sequential therapy of paclitaxel（ P） regimen,and 14 days were considered as a cycle of treatment for totally 4 cycles. Results In all patients,1 case finished chemotherapy for 1 cycle,9 cases for 4 cycles,8 cases for 5 cycles,9 cases for 6 cycles and 24 cases for 8 cycles. There were 12 patients with CR,30 with PR,8 with SD and 1 with PD. Nine patients achieved p CR,with the p CR rate and RR rate of 17. 6% and 82. 4% respectively. All patients had no grade 4 toxicities,and the main grade 3 toxicities were neutropenia（ 5. 9%） and neurotoxicity（ 2%）. The RR of both negative ER and PR was higher than that of positive ER and /or PR（ P 0. 05 or P 0. 01）. The 1-year,2-year and 3-year DFS and OS were 96. 0%,91. 0%,83. 0% and100%,95. 0%,91. 0%,respectively. Conclusion Neoadjuvant chemotherapy with dose-dense EC followed by P regimen is effective and well tolerated,which is a preferred DDNACT for patients with breast cancer.
出处
《实用临床医药杂志》
CAS
2015年第19期39-43,共5页
Journal of Clinical Medicine in Practice
基金
江苏省卫生厅科研项目(H201327)
关键词
乳腺癌
新辅助化疗
表阿霉素
环磷酰胺
紫杉醇
breast cancer
neoadjuvant chemotherapy
epirubicin
cyclophosphamide
paclitaxel
